国际肿瘤学杂志

• 综述 • 上一篇    下一篇

乳腺癌TOP2A基因与蒽环类药物疗效

  

  1. 汕头大学医学院附属肿瘤医院内科
  • 出版日期:2011-02-08 发布日期:2011-02-20

  • Online:2011-02-08 Published:2011-02-20

摘要: 含蒽环类方案目前广泛应用于乳腺癌的治疗,其疗效与拓扑异构酶Ⅱ(TOP2)基因的异常状态存在关联,已有临床研究表明HER2基因扩增伴有TOP2基因异常的患者是蒽环类治疗的主要受益人群,但该结论未达成共识。

关键词: font-family: 宋体, mso-ascii-font-family: 'Times New Roman', mso-hansi-font-family: 'Times New Roman', mso-bidi-font-family: 'Times New Roman', mso-font-kerning: 1.0pt, mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA">乳腺肿瘤, font-family: "Times New Roman", mso-font-kerning: 1.0pt, mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-fareast-font-family: 宋体">DNAfont-family: 宋体, mso-ascii-font-family: 'Times New Roman', mso-hansi-font-family: 'Times New Roman', mso-bidi-font-family: 'Times New Roman', mso-font-kerning: 1.0pt, mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA">拓扑异构酶类, Ⅱ型, 蒽环类